Covered recipient · General Payments record
MATTHEW ALEXANDER CUNNINGHAM
Allopathic & Osteopathic Physicians Ophthalmology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2023 · Entire year
$146,526.66
114 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2023 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,912.00 | 19 |
| Consulting Fee | $35,934.00 | 8 |
| Travel and Lodging | $16,044.76 | 28 |
| Food and Beverage | $4,873.01 | 55 |
| Honoraria | $3,000.00 | 2 |
| Acquisitions | $1,662.90 | 1 |
| Education | $99.99 | 1 |
By paying entity
PY2023 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Astellas Pharma US Inc | $47,807.50 | 27 |
| Apellis Pharmaceuticals, Inc. | $39,961.94 | 21 |
| Genentech USA, Inc. | $31,115.90 | 24 |
| Alcon Vision LLC | $14,140.12 | 18 |
| Regeneron Healthcare Solutions, Inc. | $10,006.54 | 13 |
| US Retina LLC | $1,662.90 | 1 |
| Alcon Research LLC | $1,400.00 | 1 |
| Alimera Sciences, Inc. | $223.81 | 3 |
| Mallinckrodt Hospital Products Inc. | $117.10 | 2 |
| AbbVie Inc. | $74.80 | 3 |
| EyePoint Pharmaceuticals US, Inc. | $16.05 | 1 |
Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MATTHEW ALEXANDER CUNNINGHAM
NPI 1336303247 · CMS profile ID 150859
Allopathic & Osteopathic Physicians / Ophthalmology
ORLANDO, FL
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1336303247?year=2023&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MATTHEW ALEXANDER CUNNINGHAM, NPI 1336303247, CMS profile ID 150859. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336303247?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- APA 7
- IndustryPayments. (2026). MATTHEW ALEXANDER CUNNINGHAM, NPI 1336303247, CMS profile ID 150859. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336303247?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
- Bluebook
- MATTHEW ALEXANDER CUNNINGHAM, NPI 1336303247, CMS profile ID 150859, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 114 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1336303247?year=2023&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2023
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30
114 matching records · $146,526.66 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 114.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Genentech USA, Inc. | $1,063.93 | 08/17/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457789 | CMS |
| Genentech USA, Inc. | $103.80 | 08/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457797 | CMS |
| Astellas Pharma US Inc | $6,200.00 | 08/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034411945 | CMS |
| Astellas Pharma US Inc | $6,200.00 | 08/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034411971 | CMS |
| Astellas Pharma US Inc | $6,200.00 | 08/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034412129 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,820.00 | 08/15/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999137975 | CMS |
| Alcon Vision LLC | $3,500.00 | 08/10/2023 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001617749 | CMS |
| Genentech USA, Inc. | $22.31 | 08/09/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457739 | CMS |
| Astellas Pharma US Inc | $22.18 | 08/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034373323 | CMS |
| Alcon Vision LLC | $22.48 | 07/30/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995943691 | CMS |
| Alcon Vision LLC | $248.11 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001616647 | CMS |
| Alcon Vision LLC | $283.20 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001616659 | CMS |
| Alcon Vision LLC | $300.30 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001616671 | CMS |
| Alcon Vision LLC | $330.37 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001616683 | CMS |
| Alcon Vision LLC | $378.90 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001616695 | CMS |
| Alcon Vision LLC | $548.90 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001616705 | CMS |
| Alcon Vision LLC | $732.99 | 07/29/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1001616717 | CMS |
| Alcon Vision LLC | $135.16 | 07/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995943697 | CMS |
| Alcon Vision LLC | $155.00 | 07/29/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995943703 | CMS |
| Astellas Pharma US Inc | $2,000.00 | 07/25/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034329761 | CMS |
| Astellas Pharma US Inc | $298.80 | 07/20/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034310115 | CMS |
| Astellas Pharma US Inc | $1,023.63 | 07/18/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034295349 | CMS |
| Astellas Pharma US Inc | $114.75 | 07/18/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034297797 | CMS |
| Astellas Pharma US Inc | $143.96 | 07/17/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034290131 | CMS |
| Astellas Pharma US Inc | $1,315.31 | 07/13/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034278728 | CMS |
| Astellas Pharma US Inc | $138.68 | 07/13/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1034280881 | CMS |
| Mallinckrodt Hospital Products Inc. | $17.11 | 07/12/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1042820561 | CMS |
| Apellis Pharmaceuticals, Inc. | $5,670.00 | 06/28/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056359153 | CMS |
| Apellis Pharmaceuticals, Inc. | $1,322.11 | 06/26/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056311877 | CMS |
| Apellis Pharmaceuticals, Inc. | $123.12 | 06/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056351377 | CMS |
| Genentech USA, Inc. | $29.62 | 06/21/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457715 | CMS |
| Alcon Vision LLC | $147.30 | 06/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995943701 | CMS |
| AbbVie Inc. | $25.60 | 05/10/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 996560437 | CMS |
| Apellis Pharmaceuticals, Inc. | $6,246.00 | 05/08/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056355483 | CMS |
| Apellis Pharmaceuticals, Inc. | $103.85 | 05/04/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056333141 | CMS |
| Apellis Pharmaceuticals, Inc. | $327.80 | 05/04/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056333151 | CMS |
| Apellis Pharmaceuticals, Inc. | $743.55 | 05/04/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056366231 | CMS |
| Apellis Pharmaceuticals, Inc. | $6,246.00 | 05/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056365147 | CMS |
| Alcon Vision LLC | $34.96 | 04/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 995943693 | CMS |
| Apellis Pharmaceuticals, Inc. | $124.15 | 04/27/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056311867 | CMS |
| Apellis Pharmaceuticals, Inc. | $263.80 | 04/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056333131 | CMS |
| Apellis Pharmaceuticals, Inc. | $183.96 | 04/27/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056352881 | CMS |
| Genentech USA, Inc. | $24.63 | 04/26/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457723 | CMS |
| Apellis Pharmaceuticals, Inc. | $39.49 | 04/14/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056330155 | CMS |
| Regeneron Healthcare Solutions, Inc. | $28.32 | 04/05/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 999137969 | CMS |
| Genentech USA, Inc. | $1,177.16 | 04/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457803 | CMS |
| Genentech USA, Inc. | $212.27 | 04/03/2023 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457811 | CMS |
| Genentech USA, Inc. | $134.30 | 04/03/2023 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457819 | CMS |
| Genentech USA, Inc. | $5,640.00 | 04/03/2023 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1040457827 | CMS |
| Apellis Pharmaceuticals, Inc. | $1,500.00 | 03/29/2023 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1056325931 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $8,282.45 | 4 |
| PY2025 | Principal investigator | $932,857.15 | 327 |
| PY2024 | Recipient | $21,476.61 | 17 |
| PY2024 | Principal investigator | $915,142.20 | 265 |
| PY2023 | Recipient | $2,205.25 | 2 |
| PY2023 | Principal investigator | $208,426.12 | 33 |
| PY2022 | Recipient | $1,320.00 | 1 |
| PY2022 | Principal investigator | $199,502.53 | 12 |
| PY2021 | Principal investigator | $150,309.24 | 30 |
| PY2020 | Principal investigator | $74,243.00 | 16 |
| PY2019 | Principal investigator | $45,336.55 | 3 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
331 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184279656 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $236.25 | 12/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184279658 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 12/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184279660 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 12/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184279662 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184277290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184277292 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 12/18/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184277294 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270537 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270539 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270541 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270553 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270555 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270557 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270559 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270561 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270565 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270567 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270569 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270575 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,680.10 | 12/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184270579 |
| Principal investigator 1 | Genentech, Inc. | $13.96 | 12/10/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211606529 |
| Principal investigator 1 | Genentech, Inc. | $3,173.68 | 12/09/2025 | Non-covered Recipient Entity Florida Retina Institute | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211606370 |
| Principal investigator 1 | Genentech, Inc. | $5,500.00 | 12/05/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211606515 |
| Principal investigator 1 | Genentech, Inc. | $7,086.00 | 12/05/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211606520 |
| Principal investigator 1 | Genentech, Inc. | $6,103.53 | 12/05/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211606534 |
| Principal investigator 1 | ABBVIE INC. | $11,162.00 | 12/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | No dispute reported | 06/30/2026 | 1202528820 |
| Principal investigator 1 | Genentech, Inc. | $13.96 | 12/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | PH III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN COPD | No dispute reported | 06/30/2026 | 1211606538 |
| Principal investigator 1 | Genentech, Inc. | $532.00 | 12/01/2025 | Non-covered Recipient Entity Florida Retina Institute | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211606374 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267011 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $405.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267013 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $142.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267015 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $82.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267017 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267019 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267021 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $149.00 | 12/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184267023 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265587 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 11/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265589 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $109.34 | 11/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184265591 |
| Principal investigator 1 | ABBVIE INC. | $6,120.00 | 11/26/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) | No dispute reported | 06/30/2026 | 1202525666 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 11/24/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184263969 |
| Principal investigator 1 | Genentech, Inc. | $35,920.00 | 11/20/2025 | Non-covered Recipient Entity Retina Group d/b/a Retina Consultants of America | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211645733 |
| Principal investigator 1 | Genentech, Inc. | $26,430.00 | 11/19/2025 | Non-covered Recipient Entity Florida Retina Institute | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211606368 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 11/17/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261543 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 11/17/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261545 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 11/17/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261547 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 11/17/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261549 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 11/17/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261551 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $314.00 | 11/17/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184261553 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $5,000.00 | 11/12/2025 | Non-covered Recipient Entity RETINA VITREOUS CONSULTANTS LLPRETINA GROUP OF FLORIDA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250238533 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $142,530.00 | 11/12/2025 | Non-covered Recipient Entity RETINA VITREOUS CONSULTANTS LLPRETINA GROUP OF FLORIDA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250238535 |
| Principal investigator 1 | Genentech, Inc. | $9,520.00 | 11/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211606510 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254327 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254329 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254331 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254333 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/29/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184254335 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253276 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253278 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253282 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253284 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253286 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253288 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253290 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253292 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253294 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253298 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253300 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,531.60 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253302 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253304 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253306 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253308 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253310 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253312 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/27/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184253314 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184252916 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184252918 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184252920 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 10/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184252922 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 10/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184252924 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 10/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184252926 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,638.60 | 10/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184252928 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/22/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184251648 |
| Principal investigator 1 | Genentech, Inc. | $6,000.00 | 10/16/2025 | Non-covered Recipient Entity Florida Retina Institute | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211606360 |
| Principal investigator 1 | Genentech, Inc. | $1,230.00 | 10/16/2025 | Non-covered Recipient Entity Florida Retina Institute | Constance Faricimab in nAMD patients | No dispute reported | 06/30/2026 | 1211606364 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 10/13/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184249869 |
| Principal investigator 1 | Ocular Therapeutix, Inc. | $200.00 | 10/09/2025 | Non-covered Recipient Entity RETINA VITREOUS CONSULTANTS LLPRETINA GROUP OF FLORIDA | Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (axitinib Implant) in Subjects with Neovascular Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1250238573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $10.92 | 10/08/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247420 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $88.20 | 10/08/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247422 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $36.82 | 10/08/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184247424 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245337 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245341 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245343 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245345 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245347 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245349 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245351 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245353 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245355 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,314.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245357 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245359 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245361 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245365 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $162.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245367 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 10/03/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184245369 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 09/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184242541 |
| Principal investigator 1 | Genentech, Inc. | $12.68 | 09/24/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211606493 |
| Principal investigator 1 | Genentech, Inc. | $2,818.00 | 09/24/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211606497 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,639.35 | 09/24/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184241968 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235937 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235939 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 09/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184235941 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $680.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410388 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $150.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410476 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $121.18 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410590 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $276.91 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410642 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,012.50 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410686 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $87.75 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410692 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410758 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,500.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410864 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,000.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410904 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,077.60 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410906 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $875.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410910 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $250.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410912 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,344.14 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410974 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,976.75 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225410990 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $87.75 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411036 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $228.33 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411144 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,000.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411194 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $21,600.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411318 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $4,813.69 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411396 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $2,500.00 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411414 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $1,181.25 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411418 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $87.75 | 09/08/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225411424 |
| Recipient | F. Hoffmann-La Roche AG | $565.91 | 08/29/2025 | Covered Recipient Physician | Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US | No dispute reported | 06/30/2026 | 1211537583 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/28/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232244 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/28/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/28/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184232248 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227943 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227945 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $113.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227947 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227949 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227951 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227953 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $135.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227955 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $203.00 | 08/14/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184227957 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 08/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184225961 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 08/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184225963 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224544 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224548 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224550 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224552 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 08/06/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184224554 |
| Principal investigator 1 | Genentech, Inc. | $14,692.00 | 08/01/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211606505 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $882.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222206 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $474.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222208 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,205.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222210 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $720.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222212 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,680.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222214 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $504.00 | 07/30/2025 | Non-covered Recipient Entity RETINA GROUP INC | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184222216 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218525 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218527 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218529 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218531 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218533 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218535 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/25/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184218563 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215048 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215050 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215052 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215054 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215062 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215064 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215066 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 07/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184215068 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.00 | 07/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214664 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214666 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $371.00 | 07/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214668 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $155.00 | 07/11/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184214670 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $474.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $720.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213165 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,000.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213167 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,680.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213171 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $882.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $504.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213177 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $6,300.00 | 07/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184213179 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209484 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209486 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209488 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209490 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209492 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209494 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209496 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $148.50 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209498 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209504 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209506 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209508 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209510 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209512 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209514 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209516 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209518 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209520 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209522 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.75 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209524 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $195.78 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209526 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $390.88 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209698 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209716 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $500.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209718 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $654.74 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $654.74 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209742 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $654.74 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209744 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209764 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,638.68 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209848 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,638.68 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209850 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $50.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209890 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,838.00 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184209910 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $59.40 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184210016 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $59.40 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184210018 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $59.40 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184210020 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.25 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184210036 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.25 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184210040 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $101.25 | 06/20/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184210042 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,000.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184203833 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,000.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | No dispute reported | 06/30/2026 | 1184203861 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203977 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203979 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203981 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203983 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203985 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203987 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203989 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203993 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184203999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184204001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184204003 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184204005 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 06/04/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184204007 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201987 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201989 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201991 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201993 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201995 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201997 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184201999 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202001 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202679 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202681 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $4,436.10 | 06/02/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184202683 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 05/26/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 05/26/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184198739 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $15,279.49 | 05/15/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | New Day Study | No dispute reported | 06/30/2026 | 1248567661 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $15,279.49 | 05/15/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | New Day Study | No dispute reported | 06/30/2026 | 1248567675 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184193671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,026.00 | 05/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184193673 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 04/28/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406608 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 04/28/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407086 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 04/28/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407126 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,485.00 | 04/24/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | New Day Study | No dispute reported | 06/30/2026 | 1248567615 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186159 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186161 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186163 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186165 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186167 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186169 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186171 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,639.60 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186173 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 04/23/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184186175 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183516 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183518 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183520 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183522 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183524 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183526 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183528 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $100.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183530 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $68.00 | 04/16/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184183532 |
| Recipient | F. Hoffmann-La Roche AG | $607.27 | 03/31/2025 | Covered Recipient Physician | Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US | No dispute reported | 06/30/2026 | 1211537587 |
| Recipient | F. Hoffmann-La Roche AG | $607.27 | 03/31/2025 | Covered Recipient Physician | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211537591 |
| Recipient | F. Hoffmann-La Roche AG | $6,502.00 | 03/31/2025 | Covered Recipient Physician | Treatment Response and Safety of Faricimab in Underrepresented Patients With DME: Year 1 Results From ELEVATUM in the US | No dispute reported | 06/30/2026 | 1211537595 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 03/24/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225403823 |
| Principal investigator 1 | Genentech, Inc. | $23,023.00 | 03/21/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211606490 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $85,814.19 | 03/19/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | New Day Study | No dispute reported | 06/30/2026 | 1248567671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184173236 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184173238 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184173240 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184173242 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184173244 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184173246 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,225.85 | 03/12/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A PHASE 3B SINGLE-ARM STUDY OF AFLIBERCEPT 8 MG IN PARTICIPANTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (NAMD) OR DIABETIC MACULAR EDEMA (DME) | No dispute reported | 06/30/2026 | 1184173248 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 02/28/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406466 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/27/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225402763 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/27/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225403183 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/27/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225404189 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/27/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405814 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/27/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406610 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 02/27/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407128 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $1,950.30 | 02/24/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | New Day Study | No dispute reported | 06/30/2026 | 1248567581 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $2,100.00 | 02/21/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | New Day Study | No dispute reported | 06/30/2026 | 1248567491 |
| Principal investigator 1 | ANI Pharmaceuticals, Inc. | $750.00 | 02/17/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | New Day Study | No dispute reported | 06/30/2026 | 1248567417 |
| Principal investigator 1 | Genentech, Inc. | $1,592.00 | 02/07/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | Faricimab for Under represented Patients with DME | No dispute reported | 06/30/2026 | 1211606485 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,500.00 | 02/05/2025 | Non-covered Recipient Entity FLORIDA RETINA INSTITUTE | A Multicenter, Randomized, Double-Masked, Placebo-Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration | No dispute reported | 06/30/2026 | 1184152266 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,684.10 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225402761 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225403567 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405106 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405108 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405746 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225405748 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406440 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225406442 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,003.70 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407082 |
| Principal investigator 1 | Bayer Healthcare Pharmaceuticals Inc. | $3,850.15 | 01/30/2025 | Non-covered Recipient Entity Florida Retina Institute Orlando | BAY 865321, Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Aflibercept 8 mg in Macular Edema Secondary to Retinal Vein Occlusion | No dispute reported | 06/30/2026 | 1225407084 |
Ownership and Investment Interests
One row per program year and measure, newest year first · the amount invested and the value of the interest are never added together
| Program year | Measure | Amount | Records |
|---|---|---|---|
| PY2023 | Amount invested | $0.00 | 1 |
| PY2023 | Value of interest | $3,187.10 | 1 |
| PY2022 | Amount invested | $0.00 | 1 |
| PY2022 | Value of interest | $2,500.00 | 1 |
| PY2021 | Amount invested | $0.00 | 1 |
| PY2021 | Value of interest | $2,500.00 | 1 |
| PY2020 | Amount invested | $0.00 | 1 |
| PY2020 | Value of interest | $2,777.78 | 1 |
| PY2019 | Amount invested | $0.00 | 1 |
| PY2019 | Value of interest | $2,777.78 | 1 |
Ownership and Investment Interests are a separate CMS dataset, shown here separately and never added to payments.
Ownership and investment interests are reported as the value of an interest held, not as a payment received. They are a different measure from the payment total on this page and are never combined with it.
Ownership and Investment Interests records
Ordering applied by this site (program year, newest first, then company) · record values are shown as CMS published them
5 records · PY2019–2023
| Program year | Company | Amount invested | Value of interest | Terms of interest | Interest held by | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| PY2023 | US Retina LLC | $0.00 | $3,187.10 | Membership Interest | Physician Covered Recipient | No dispute reported | 06/30/2026 | 1052376703 |
| PY2022 | US Retina LLC | $0.00 | $2,500.00 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 951869602 |
| PY2021 | US Retina LLC | $0.00 | $2,500.00 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 856668973 |
| PY2020 | US Retina LLC | $0.00 | $2,777.78 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 714311267 |
| PY2019 | US Retina LLC | $0.00 | $2,777.78 | Shares | Physician Covered Recipient | No dispute reported | 06/30/2026 | 655842699 |